(414) pH-Responsive Doxorubicin Dimeric Nanoassemblies with High Loading, Stability, and Tumor Selectivity
Introduction: Doxorubicin is widely used for treating solid tumors, but its clinical use is limited by cardiotoxicity [1]. Doxil, the first FDA-approved nanomedicine, mitigates this; however, it still faces significant limitations, including low drug loading (11%), suboptimal drug release at tumor-site, and continued dose-limiting toxicity, restricting its antitumor efficacy [2]. To address these, we developed imine-based pH-responsive doxorubicin dimeric nanoparticles stabilized with DSPE-PEG, designed for tumor-specific drug release and reduced systemic toxicity for improved cancer therapy.
Learning Objectives:
Understand the rationale for developing a pH-responsive doxorubicin dimeric nanomedicine.
Describe how DSPE-PEG coating improves the stability and antitumor efficacy of nanoparticles.
Evaluate therapeutic benefits and safety of prodrug-based nanoparticles compared to Dox and Doxil.
